Effect of Vitamin D on clinical and biochemical parameters in polycystic ovary syndrome women: A meta-analysis

Journal of Obstetrics and Gynaecology Research

Volumn 41, Issue 11, 2015, Pages 1791-1802

  Jia, Xin Zhuan ^a   Wang, Yong Mei ^a   Zhang, Na ^a   Guo, Li Na ^a   Zhen, Xiu Li ^a   Li, Hui ^b   Wei, Lan ^b  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Hebei Chest Hospital   (China)

Author keywords

endocrine disorder; polycystic ovary syndrome; therapeutic effect; Vitamin D; Vitamin D3 supplementation

Indexed keywords

25 HYDROXYVITAMIN D; COLECALCIFEROL; PARATHYROID HORMONE; VITAMIN D;

ARTICLE; CLINICAL FEATURE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; META ANALYSIS; OVARY POLYCYSTIC DISEASE; PARATHYROID HORMONE BLOOD LEVEL; SYSTEMATIC REVIEW; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION; BLOOD; FEMALE; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME;

FEMALE; HUMANS; POLYCYSTIC OVARY SYNDROME; TREATMENT OUTCOME; VITAMIN D;

EID: 84946497534     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12793     Document Type: Article

References (48)

1. Patra SK, Nasrat H, Goswami B, Jain A,. Vitamin D as a predictor of insulin resistance in polycystic ovarian syndrome. Diabetes Metab Syndr 2012; 6: 146-149.
2. Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK,. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism 2011; 60: 1475-1481.
3. Ardabili HR, Gargari BP, Farzadi L,. Vitamin D supplementation has no effect on insulin resistance assessment in women with polycystic ovary syndrome and vitamin D deficiency. Nutr Res 2012; 32: 195-201.
4. Firouzabadi R, Aflatoonian A, Modarresi S, Sekhavat L, MohammadTaheri S,. Therapeutic effects of calcium & vitamin D supplementation in women with PCOS. Complement Ther Clin Pract 2012; 18: 85-88.
5. Wehr E, Trummer O, Giuliani A, Gruber HJ, Pieber TR, Obermayer-Pietsch B,. Vitamin D-associated polymorphisms are related to insulin resistance and vitamin D deficiency in polycystic ovary syndrome. Eur J Endocrinol 2011; 164: 741-749.
6. Gulseth HL, Gjelstad IM, Tierney AC, et al,. Serum vitamin D concentration does not predict insulin action or secretion in European subjects with the metabolic syndrome. Diabetes Care 2010; 33: 923-925.
7. George PS, Pearson ER, Witham MD,. Effect of vitamin D supplementation on glycaemic control and insulin resistance: A systematic review and meta-analysis. Diabet Med 2012; 29: e142-e150.
8. Dalgard C, Petersen MS, Weihe P, Grandjean P,. Vitamin D status in relation to glucose metabolism and type 2 diabetes in septuagenarians. Diabetes Care 2011; 34: 1284-1288.
9. Pramyothin P, Biancuzzo RM, Lu Z, Hess DT, Apovian CM, Holick MF,. Vitamin D in adipose tissue and serum 25-hydroxyvitamin D after roux-en-Y gastric bypass. Obesity (Silver Spring) 2011; 19: 2228-2234.
10. Pinelli NR, Jaber LA, Brown MB, Herman WH,. Serum 25-hydroxy vitamin d and insulin resistance, metabolic syndrome, and glucose intolerance among Arab Americans. Diabetes Care 2010; 33: 1373-1375.
11. Scragg R, Sowers M, Bell C,. Third National Health and Nutrition Examination Survey. Serum 25-hydroxyvitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 2004; 27: 2813-2818.
12. Hutchinson MS, Grimnes G, Joakimsen RM, Figenschau Y, Jorde R,. Low serum 25-hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general population: The Tromsø study. Eur J Endocrinol 2010; 162: 935-942.
13. Tao MF, Zhang Z, Ke YH, et al,. Association of serum 25-hydroxyvitamin D with insulin resistance and beta-cell function in a healthy Chinese female population. Acta Pharmacol Sin 2013; 34: 1070-1074.
14. Bellia A, Garcovich C, D'Adamo M, et al,. Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med 2013; 8: 33-40.
15. Kim JJ, Choi YM, Chae SJ, et al,. Vitamin D deficiency in women with polycystic ovary syndrome. Clin Exp Reprod Med 2014; 41: 80-85.
16. Thomson RL, Spedding S, Buckley JD,. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol (Oxf) 2012; 77: 343-350.
17. Naqvi SH, Moore A, Bevilacqua K, et al,. Predictors of depression in women with polycystic ovary syndrome. Arch Womens Ment Health 2014; 18: 95-101.
18. Raja-Khan N, Shah J, Stetter CM, et al,. High-dose vitamin D supplementation and measures of insulin sensitivity in polycystic ovary syndrome: A randomized, controlled pilot trial. Fertil Steril 2014; 101: 1740-1746.
19. Gallea M, Granzotto M, Azzolini S, et al,. Insulin and body weight but not hyperandrogenism seem involved in seasonal serum 25-OH-vitamin D3 levels in subjects affected by PCOS. Gynecol Endocrinol 2014; 30: 739-745.
20. Yildizhan R, Kurdoglu M, Adali E, et al,. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet 2009; 280: 559-563.
21. Irani M, Minkoff H, Seifer DB, Merhi Z,. Vitamin D increases serum levels of the soluble receptor for advanced glycation end products in women with PCOS. J Clin Endocrinol Metab 2014; 99: E886-E890.
22. Irani M, Seifer D, Minkoff H, Merhi Z,. Vitamin d normalizes abnormally elevated serum antimullerian hormone levels usually noted in women with polycystic ovary syndrome. Obstet Gynecol 2014; 123: 189S.
23. Kotsa K, Yavropoulou MP, Anastasiou O, Yovos JG,. Role of vitamin D treatment in glucose metabolism in polycystic ovary syndrome. Fertil Steril 2009; 92: 1053-1058.
24. Rotterdam EA-SPcwg,. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
25. Zawadzki JK, Dunaif A,. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach[J]. Polycystic ovary syndrome. Boston: Blackwell Scientific, 1992; 377-384.
26. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J,. Methodological index for non-randomized studies (minors): Development and validation of a new instrument. ANZ J Surg 2003; 73: 712-716.
27. Zintzaras E, Ioannidis JP,. HEGESMA: Genome search meta-analysis and heterogeneity testing. Bioinformatics 2005; 21: 3672-3673.
28. Zintzaras E, Ioannidis JP,. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005; 28: 123-137.
29. Higgins JP, Thompson SG,. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21: 1539-1558.
30. Egger M, Davey Smith G, Schneider M, Minder C,. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
31. Mahmoudi T, Gourabi H, Ashrafi M, Yazdi RS, Ezabadi Z,. Calciotropic hormones, insulin resistance, and the polycystic ovary syndrome. Fertil Steril 2010; 93: 1208-1214.
32. Yan WJ, Yang J, Zhang B, Yin TL, Jie Z,. Preliminary study on the relationship between vitamin D and polycystic ovary syndrome. Prog Obstet Gynaecol 2010; 19: 844-846.
33. Savastano S, Valentino R, Di Somma C, et al,. Serum 25-Hydroxyvitamin D levels, phosphoprotein enriched in diabetes gene product (PED/PEA-15) and leptin-to-adiponectin ratio in women with PCOS. Nutr Metab (Lond) 2011; 8: 84. http://www.nutritionandmetabolism.com/content/8/1/84
34. Wehr E, Pieber TR, Obermayer-Pietsch B,. Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: A pilot study. J Endocrinol Invest 2011; 34: 757-763.
35. Lin MW, Tsai SJ, Chou PY, Huang MF, Sun HS, Wu MH,. Vitamin D receptor 1a promotor -1521 G/C and -1012 A/G polymorphisms in polycystic ovary syndrome. Taiwan J Obstet Gynecol 2012; 51: 565-571.
36. Mazloomi S, Sharifi F, Hajihosseini R, Kalantari S, Mazloomzadeh S,. Association between hypoadiponectinemia and low serum concentrations of calcium and vitamin D in women with polycystic ovary syndrome. ISRN Endocrinol 2012; 2012: 949427.
37. Tsakova AD, Gateva AT, Kamenov ZA,. 25(OH) vitamin D levels in premenopausal women with polycystic ovary syndrome and/or obesity. Int J Vitam Nutr Res 2012; 82: 399-404.
38. El-Shal AS, Shalaby SM, Aly NM, Rashad NM, Abdelaziz AM,. Genetic variation in the vitamin D receptor gene and vitamin D serum levels in Egyptian women with polycystic ovary syndrome. Mol Biol Rep 2013; 40: 6063-6073.
39. Jie M, Di W, Ji-hui A, Lie-gang L, Han-wang Z,. The correlation analysis of serum 25 hydroxyvitamin D levels and polycystic ovarian syndrome. J Huazhong Univ Sci Tech 2013; 28: 1333-1335.
40. Selimoglu H, Duran C, Kiyici S, et al,. The effect of vitamin D replacement therapy on insulin resistance and androgen levels in women with polycystic ovary syndrome. J Endocrinol Invest 2010; 33: 234-238.
41. Pal L, Berry A, Coraluzzi L, et al,. Therapeutic implications of vitamin D and calcium in overweight women with polycystic ovary syndrome. Gynecol Endocrinol 2012; 28: 965-968.
42. Rahimi-Ardabili H, Pourghassem Gargari B, Farzadi L,. Effects of vitamin D on cardiovascular disease risk factors in polycystic ovary syndrome women with vitamin D deficiency. J Endocrinol Invest 2013; 36: 28-32.
43. Hahn S, Haselhorst U, Tan S, et al,. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 2006; 114: 577-583.
44. Manneras-Holm L, Leonhardt H, Kullberg J, et al,. Adipose tissue has aberrant morphology and function in PCOS: Enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 2011; 96: E304-E311.
45. Sung CC, Liao MT, Lu KC, Wu CC,. Role of vitamin D in insulin resistance. J Biomed Biotechnol 2012; 2012: 634195.
46. Jorde R, Figenschau Y,. Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr 2009; 48: 349-354.
47. von Hurst PR, Stonehouse W, Coad J,. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient-a randomised, placebo-controlled trial. Br J Nutr 2010; 103: 549-555.
48. Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD,. The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: A randomised controlled trial. Diabetologia 2010; 53: 2112-2119.